Inactive Instrument

Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Biotechnology & Medical Research

Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference

September 01, 2021 at 08:01 am EDT

NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will present at the virtual Baird 2021 Global Healthcare Conference on Tuesday, September 14, 2021 at 10:15 a.m. ET.

A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

CONTACT

For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com

Media inquiries: media@interceptpharma.com

Latest news about Intercept Pharmaceuticals, Inc.

North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023	Nov. 13	CI
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023	Nov. 10	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Composite Index	Nov. 08	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P TMI Index	Nov. 08	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Global BMI Index	Nov. 08	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Biotechnology Select Industry Index	Nov. 08	CI
Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..	Nov. 07	CI
North American Morning Briefing : Higher Bond -2-	Nov. 07	DJ
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Biotechnology Index	Nov. 07	CI
Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors	23-10-23	CI
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ
UBS Raises Intercept Pharmaceuticals Price Target to $19 From $12, Maintains Neutral Rating	23-09-27	MT
HC Wainwright Downgrades Intercept Pharmaceuticals to Neutral From Buy, Price Target is $19	23-09-27	MT
Canaccord Genuity Downgrades Intercept Pharmaceuticals to Hold From Buy, Trims Price Target to $19 From $20	23-09-27	MT
RBC Raises Price Target on Intercept Pharmaceuticals to $19 From $12 on Deal to Be Bought by Alfasigma; Sector Perform Kept	23-09-27	MT
B. Riley Downgrades Intercept Pharmaceuticals to Neutral From Buy After Announced Sale to Alfasigma, Lifts PT to $19 From $15	23-09-27	MT
Sector Update: Health Care Stocks Lower Late Tuesday Afternoon	23-09-26	MT
Sector Update: Health Care Stocks Declining in Afternoon Trading	23-09-26	MT
Intercept Pharmaceuticals Agrees to be Acquired by Alfasigma for $19 Per Share; Stock Soars Pre-Bell	23-09-26	MT
Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln	23-09-26	RE
UBS Adjusts Intercept Pharmaceuticals Price Target to $12 From $20, Maintains Neutral Rating	23-08-14	MT
Transcript : Intercept Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 02, 2023	23-08-02
Earnings Flash (ICPT) INTERCEPT PHARMACEUTICALS Reports Q2 Revenue $83.7M, vs. Street Est of $79.6M	23-08-02	MT

Chart Intercept Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company's marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs